Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2010 Publisher: Alliance Pharmaceuticals Ltd, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, UK
Edrophonium Injection BP is an antagonist to cholinesterase, the enzyme which normally destroys acetylcholine. The action of Edrophonium Injection BP can briefly be described, therefore, as the potentiation of naturally occurring acetylcholine. It differs from Prostigmin (neostigmine) and Mestinon (pyridostigmine) in the rapidity and brevity of its action.
Following intravenous injection of Edrophonium Injection BP an initial rapid phase of elimination (0.5-2 minutes) precedes a much slower decline (24-45 minutes). It is suggested that the rapid fall in plasma concentration of edrophonium is not primarily due to metabolism and excretion but to the rapid uptake of the drug by other tissues.
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
